Dias E Silva Douglas, Borad Mitesh, Uson Junior Pedro Luiz Serrano
Department of Oncology, Hospital Israelita Albert Einstein, São Paulo 05652900, Sao Paulo, Brazil.
Division of Hematology-Oncology, Department of Medicine, Mayo Clinic Arizona, Mayo Clinic Cancer Center, Phoenix, AZ 85054, United States.
World J Gastrointest Oncol. 2024 Dec 15;16(12):4766-4769. doi: 10.4251/wjgo.v16.i12.4766.
Newer systemic therapies for hepatocellular carcinoma (HCC) have led to growing interest in combining hepatic arterial infusion chemotherapy (HAIC) with systemic treatments. To evaluate the effectiveness and safety of HAIC and combination therapies in treating advanced HCC, a network meta-analysis was conducted by Zhou . The study included data from 44 articles. HAIC was superior in overall survival (OS), progression-free survival (PFS), and response rates compared to transarterial chemoembolization and sorafenib. Moreover, combinations of HAIC with other treatments and single agents (, lenvatinib, ablation, anti-programmed cell death 1 therapy, radiotherapy) provided better OS and PFS outcomes than HAIC alone. In this editorial, we will discuss the study findings, the strengths and weaknesses of the metanalysis, and future advances in the field of HAIC for advanced HCC.
肝细胞癌（HCC）的新型全身治疗方法引发了人们对肝动脉灌注化疗（HAIC）与全身治疗相结合的兴趣日益浓厚。为了评估HAIC及联合疗法治疗晚期HCC的有效性和安全性，周进行了一项网状荟萃分析。该研究纳入了44篇文章的数据。与经动脉化疗栓塞术和索拉非尼相比，HAIC在总生存期（OS）、无进展生存期（PFS）和缓解率方面更具优势。此外，HAIC与其他治疗方法及单一药物（如乐伐替尼、消融、抗程序性细胞死亡1疗法、放射治疗）联合使用时，其OS和PFS结果优于单独使用HAIC。在这篇社论中，我们将讨论该研究结果、荟萃分析的优缺点以及晚期HCC的HAIC领域的未来进展。
